Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Male Subjects

Trial Profile

Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs AC 083 (Primary)
  • Indications Neurological disorders
  • Focus Adverse reactions; First in man
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 13 Jan 2017 Status changed from recruiting to completed.
    • 01 Nov 2016 Planned number of patients changed from 48 to 72.
    • 01 Nov 2016 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top